Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Peking University Third Hospital, Beijing, Beijing Municipality Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality West China Hospital，Sichuan University, Chengdu, Sichuan